GHENT,  Belgium,  1 October  2010 -  Ablynx  [Euronext  Brussels:  ABLX] today
announced  that it will receive further  milestone payments totalling EUR3 million
from  Boehringer Ingelheim, triggered as part  of its strategic alliance for the
development  and  commercialisation  of  Nanobodies(®).  Ablynx has now earned a
total of EUR12 million in milestone payments as part of this agreement.

Ablynx  and Boehringer Ingelheim entered into  an agreement in September 2007 to
collaborate  on the  discovery, development  and commercialisation  of up to 10
different  Nanobody therapeutics across  a range of  areas including for example
immunology,  oncology  and  respiratory  diseases.  The  agreement  would  allow
potential  milestone payments of up to  EUR125 million for each Nanobody developed
as  well as undisclosed royalties to Ablynx. Boehringer Ingelheim is exclusively
responsible  for  the  development,  manufacture  and  commercialisation  of any
products  resulting from the collaboration.  Ablynx retains certain co-promotion
rights in Europe.

Dr  Edwin Moses,  CEO and  Chairman of  Ablynx, said:  "We are  pleased that yet
another  Nanobody programme has reached this contractual milestone. The Nanobody
platform  continues to  deliver across  therapeutic areas  and also  for complex
targets."

                                     -ends-

 About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on  the discovery  and development  of Nanobodies,  a novel class of therapeutic
proteins  based on single-domain antibody fragments,  for a range of serious and
life-threatening  human diseases. The Company  currently has over 250 employees.
Ablynx  completed a  successful IPO  on Euronext  Brussels [ABLX]  on 7 November
2007 and raised EUR50 million through an SPO in March 2010.

Ablynx  is developing a portfolio of  Nanobody-based therapeutics in a number of
major   disease   areas,   including   inflammation,  thrombosis,  oncology  and
Alzheimer's  disease.  Ablynx  now  has  over  25 programmes  in its therapeutic
pipeline  including four Nanobodies in  clinical development. So far, Nanobodies
have been successfully generated against more than 220 different protein targets
including  several complex targets  such as chemokines,  GPCRs, ion channels and
viruses,  which  are  typically  very  difficult  to  address  with conventional
monoclonal antibodies.



For more information, please contact Ablynx:

Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com



[HUG#1448178]





Cpmplete version of the press release: 
http://hugin.info/137912/R/1448178/390562.pdf




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Ablynx via Thomson Reuters ONE